Novartis Inks Deal for Peptide Therapeutics

- The deal is for cardiovascular treatments and includes an upfront payment of up to $100 million for Unnatural Products, with the potential for an additional $1.7 billion if development, regulatory, and sales milestones are met. - Unnatural Products specializes in macrocyclic peptides, a class of molecules that combine the benefits of large-molecule drugs (like antibodies) and small-molecule drugs, allowing them to hit challenging disease targets inside cells. - These "undruggable" targets are often proteins involved in disease that lack the well-defined surface pockets required for traditional small-molecule drugs to bind, or are inaccessible to larger biologic drugs. - Unnatural Products' technology platform uses machine learning and computational methods to rapidly design and test vast numbers of these peptide molecules, accelerating the discovery of potential new medicines. - A tech-focused career path in this field, like a Computational Chemist at Unnatural Products, typically involves a Ph.D. and focuses on designing molecules and analyzing data using computer models, programming, and physics-based methods. - A patient-facing role in this collaboration, such as a Clinical Development Medical Director at Novartis, requires a medical degree (MD) and years of experience in clinical research, and involves leading clinical trials, ensuring patient safety, and working with health authorities. - This collaboration is part of a larger trend where major pharmaceutical companies like Novartis partner with specialized biotech firms; Unnatural Products also has similar deals with Merck, BridgeBio, and argenx to tackle difficult targets in oncology and rare diseases.